{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:51:05Z","timestamp":1769197865884,"version":"3.49.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Keryx Biopharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40265-019-01125-w","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T09:03:48Z","timestamp":1558947828000},"page":"957-968","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Mechanism of Action and Clinical Attributes of Auryxia\u00ae (Ferric Citrate)"],"prefix":"10.1007","volume":"79","author":[{"given":"Tomas","family":"Ganz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Bino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidro B.","family":"Salusky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,27]]},"reference":[{"key":"1125_CR1","first-page":"151","volume":"5","author":"L Braun","year":"2012","unstructured":"Braun L, Sood V, Hogue S, et al. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012;5:151\u201363.","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"1125_CR2","unstructured":"United States Renal Data System. 2017 USRDS annual data report: executive summary [online]. \n                    https:\/\/www.usrds.org\/2017\/view\/Default.aspx\n                    \n                  . Accessed 7 June 2018."},{"issue":"5","key":"1125_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3122\/jabfm.2015.05.150070","volume":"28","author":"BM Vest","year":"2015","unstructured":"Vest BM, York TR, Sand J, et al. Chronic kidney disease guideline implementation in primary care: a qualitative report from the TRANSLATE CKD study. J Am Board Fam Med. 2015;28(5):624\u201331.","journal-title":"J Am Board Fam Med."},{"issue":"1","key":"1125_CR4","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","volume":"9","author":"ME Stauffer","year":"2014","unstructured":"Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1):e84943.","journal-title":"PLoS One."},{"issue":"4","key":"1125_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.nefro.2016.01.011","volume":"36","author":"L Salanova Villanueva","year":"2016","unstructured":"Salanova Villanueva L, Sanchez Gonzalez C, Sanchez Tomero JA, et al. Bone mineral disorder in chronic kidney disease: klotho and FGF23; cardiovascular implications. Nefrologia. 2016;36(4):368\u201375.","journal-title":"Nefrologia."},{"key":"1125_CR6","unstructured":"US-DOPPS Practice Monitor. Serum phosphorus (most recent) national sample [online]. \n                    http:\/\/www.dopps.org\/DPM\n                    \n                  . Accessed 18 Mar 2019."},{"key":"1125_CR7","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0085-2538(15)51226-X","volume":"96","author":"EA Friedman","year":"2005","unstructured":"Friedman EA. An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. Kidney Int Suppl. 2005;96:S2\u20136.","journal-title":"Kidney Int Suppl."},{"issue":"4","key":"1125_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium\u2009\u00d7\u2009phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607\u201317.","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"1125_CR9","first-page":"318","volume":"54","author":"GA Block","year":"2000","unstructured":"Block GA. Prevalence and clinical consequences of elevated Ca\u2009\u00d7\u2009P product in hemodialysis patients. Clin Nephrol. 2000;54(4):318\u201324.","journal-title":"Clin Nephrol."},{"issue":"2","key":"1125_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ki.2008.130","volume":"74","author":"KA Hruska","year":"2008","unstructured":"Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74(2):148\u201357.","journal-title":"Kidney Int."},{"issue":"6","key":"1125_CR11","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1681\/ASN.2004040275","volume":"16","author":"Y Slinin","year":"2005","unstructured":"Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16(6):1788\u201393.","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"1125_CR12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/ki.2012.176","volume":"82","author":"M Wolf","year":"2012","unstructured":"Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82(7):737\u201347.","journal-title":"Kidney Int."},{"issue":"12","key":"1125_CR13","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas G, et al. FGF23, PTH and phosphorus metabolism in the chronic renal insufficiency cohort. Kidney Int. 2011;79(12):1370\u20138.","journal-title":"Kidney Int."},{"issue":"5","key":"1125_CR14","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.2005111185","volume":"17","author":"S Liu","year":"2006","unstructured":"Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17(5):1305\u201315.","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"1125_CR15","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205\u201315.","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"1125_CR16","doi-asserted-by":"publisher","first-page":"7294","DOI":"10.1038\/s41598-018-25439-z","volume":"8","author":"KH Nam","year":"2018","unstructured":"Nam KH, Kim H, An SY, et al. Circulating fibroblast growth factor-23 levels are associated with an increased risk of anemia development in patients with nondialysis chronic kidney disease. Sci Rep. 2018;8(1):7294.","journal-title":"Sci Rep."},{"issue":"4","key":"1125_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/MNH.0000000000000232","volume":"25","author":"C Francis","year":"2016","unstructured":"Francis C, David V. Inflammation regulates fibroblast growth factor 23 production. Curr Opin Nephrol Hypertens. 2016;25(4):325\u201332.","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"7","key":"1125_CR18","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/CJN.13281211","volume":"7","author":"J Munoz Mendoza","year":"2012","unstructured":"Munoz Mendoza J, Isakova T, Ricardo AC, et al. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol. 2012;7(7):1155\u201362.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"1125_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ki.2015.290","volume":"89","author":"V David","year":"2016","unstructured":"David V, Martin A, Isakova T, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89(1):135\u201346.","journal-title":"Kidney Int."},{"issue":"7","key":"1125_CR20","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/ndt\/17.7.1170","volume":"17","author":"HH Malluche","year":"2002","unstructured":"Malluche HH, Mawad H. Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions. Nephrol Dial Transplant. 2002;17(7):1170\u20135.","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"1125_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/ndt\/17.2.336","volume":"17","author":"IB Salusky","year":"2002","unstructured":"Salusky IB, Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transpl. 2002;17(2):336\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"1125_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1056\/NEJM197601222940402","volume":"294","author":"AC Alfrey","year":"1976","unstructured":"Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976;294(4):184\u20138.","journal-title":"N Engl J Med."},{"issue":"1","key":"1125_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1\u201359.","journal-title":"Kidney Int Suppl."},{"issue":"9","key":"1125_CR24","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","volume":"72","author":"WN Suki","year":"2007","unstructured":"Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130\u20137.","journal-title":"Kidney Int."},{"issue":"1","key":"1125_CR25","doi-asserted-by":"publisher","first-page":"001","DOI":"10.17352\/acn.000004","volume":"1","author":"J Rottembourg","year":"2016","unstructured":"Rottembourg J, Rostoker G. Use of iron therapy in chronic kidney disease. Arch Clin Nephrol. 2016;1(1):001\u20133.","journal-title":"Arch Clin Nephrol."},{"issue":"5","key":"1125_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","volume":"68","author":"D Shepshelovich","year":"2016","unstructured":"Shepshelovich D, Rozen-Zvi B, Avni T, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis. 2016;68(5):677\u201390.","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"1125_CR27","doi-asserted-by":"publisher","first-page":"e2308","DOI":"10.1097\/MD.0000000000002308","volume":"95","author":"S Bonovas","year":"2016","unstructured":"Bonovas S, Fiorino G, Allocca M, et al. Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(2):e2308.","journal-title":"Medicine (Baltimore)."},{"issue":"2","key":"1125_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/ckj\/sfv142","volume":"9","author":"L Del Vecchio","year":"2016","unstructured":"Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. 2016;9(2):260\u20137.","journal-title":"Clin Kidney J."},{"issue":"suppl 1","key":"1125_CR29","doi-asserted-by":"publisher","first-page":"i9","DOI":"10.1093\/ckj\/sfx100","volume":"10","author":"SD Roger","year":"2017","unstructured":"Roger SD. Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease. Clin Kidney J. 2017;10(suppl 1):i9\u201315.","journal-title":"Clin Kidney J."},{"issue":"1","key":"1125_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1517\/17425255.2016.1110573","volume":"12","author":"AB Pai","year":"2016","unstructured":"Pai AB, Jang SM, Wegrzyn N. Iron-based phosphate binders\u2014a new element in management of hyperphosphatemia. Expert Opin Drug Metab Toxicol. 2016;12(1):115\u201327.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"1125_CR31","volume-title":"Full prescribing information","author":"Auryxia (Ferric Citrate)","year":"2017","unstructured":"Auryxia (Ferric Citrate). Full prescribing information. Boston: Keryx Biopharmaceuticals Inc.; 2017."},{"key":"1125_CR32","volume-title":"Summary of product characteristics","author":"Fexeric (Ferric Citrate Coordination Complex)","year":"2015","unstructured":"Fexeric (Ferric Citrate Coordination Complex). Summary of product characteristics. London: Keryx Biopharma UK Ltd.; 2015."},{"key":"1125_CR33","unstructured":"Torii Pharmaceuticals Co., Ltd. Mainstay products [online]. \n                    https:\/\/www.torii.co.jp\/en\/company\/product.html\n                    \n                  . Accessed 7 June 2018."},{"key":"1125_CR34","unstructured":"Pharmaceuticals and Medical Devices Agency. New drugs approved in FY 2013 [online]. \n                    https:\/\/www.pmda.go.jp\/files\/000153463.pdf\n                    \n                  . Accessed 2 May 2018."},{"key":"1125_CR35","unstructured":"Panion & BF Biotech, Inc. NEPHOXIL capsule 500\u00a0mg [online]. \n                    https:\/\/www.pbf.com.tw\/\n                    \n                  . Accessed 2 Aug 2018."},{"key":"1125_CR36","volume-title":"Data on file","author":"European Medicines Agency","year":"2018","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Data on file. Boston: Keryx Biopharmaceuticals; 2018."},{"key":"1125_CR37","doi-asserted-by":"publisher","first-page":"8616","DOI":"10.1039\/b910970f","volume":"40","author":"AM Silva","year":"2009","unstructured":"Silva AM, Kong X, Parkin MC, et al. Iron(III) citrate speciation in aqueous solution. Dalton Trans. 2009;40:8616\u201325.","journal-title":"Dalton Trans."},{"issue":"6","key":"1125_CR38","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/zfch.19880280603","volume":"28","author":"MJ Milewska","year":"1988","unstructured":"Milewska MJ. Citric-acid\u2014its natural and synthetic derivatives. Z Chem. 1988;28(6):204\u201311.","journal-title":"Z Chem."},{"issue":"1","key":"1125_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1023\/A:1009225701332","volume":"13","author":"JL Pierre","year":"2000","unstructured":"Pierre JL, Gautier-Luneau I. Iron and citric acid: a fuzzy chemistry of ubiquitous biological relevance. Biometals. 2000;13(1):91\u20136.","journal-title":"Biometals."},{"issue":"6","key":"1125_CR40","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1128\/jb.172.6.3298-3303.1990","volume":"172","author":"ML Guerinot","year":"1990","unstructured":"Guerinot ML, Meidl EJ, Plessner O. Citrate as a siderophore in Bradyrhizobium japonicum. J Bacteriol. 1990;172(6):3298\u2013303.","journal-title":"J Bacteriol."},{"issue":"3","key":"1125_CR41","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1128\/JB.112.3.1142-1149.1972","volume":"112","author":"L Langman","year":"1972","unstructured":"Langman L, Young IG, Frost GE, et al. Enterochelin system of iron transport in Escherichia coli: mutations affecting ferric-enterochelin esterase. J Bacteriol. 1972;112(3):1142\u20139.","journal-title":"J Bacteriol."},{"issue":"3","key":"1125_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/156482650702800306","volume":"28","author":"T Govindaraj","year":"2007","unstructured":"Govindaraj T, KrishnaRau L, Prakash J. In vitro bioavailability of iron and sensory qualities of iron-fortified wheat biscuits. Food Nutr Bull. 2007;28(3):299\u2013306.","journal-title":"Food Nutr Bull."},{"issue":"3","key":"1125_CR43","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/gut.10.3.226","volume":"10","author":"A Jacobs","year":"1969","unstructured":"Jacobs A, Miles PM. Role of gastric secretion in iron absorption. Gut. 1969;10(3):226\u20139.","journal-title":"Gut."},{"key":"1125_CR44","doi-asserted-by":"publisher","first-page":"846824","DOI":"10.1100\/2012\/846824","volume":"2012","author":"P Santiago","year":"2012","unstructured":"Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. Sci World J. 2012;2012:846824.","journal-title":"Sci World J"},{"issue":"50","key":"1125_CR45","doi-asserted-by":"publisher","first-page":"13266","DOI":"10.1021\/ja9807035","volume":"120","author":"M Matzapetakis","year":"1998","unstructured":"Matzapetakis M, Raptopoulou CP, Tsohos A, et al. Synthesis, spectroscopic and structural characterization of the first mononuclear, water soluble iron\u2013citrate complex, (NH4)5Fe(C6H4O7)2\u00b72H2O. J Am Chem Soc. 1998;120(50):13266\u20137.","journal-title":"J Am Chem Soc."},{"issue":"23","key":"1125_CR46","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.1021\/ic00101a001","volume":"33","author":"I Shweky","year":"1994","unstructured":"Shweky I, Bino A, Goldberg DP, et al. Syntheses, structures, and magnetic properties of two dinuclear iron(III) citrate complexes. Inorg Chem. 1994;33(23):5161\u20132.","journal-title":"Inorg Chem."},{"issue":"20","key":"1125_CR47","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1021\/ic9715658","volume":"37","author":"A Bino","year":"1998","unstructured":"Bino A, Shweky I, Cohen S, et al. A novel nonairon(III) citrate complex: a \u201cferric triple-decker\u201d. Inorg Chem. 1998;37(20):5168\u201372.","journal-title":"Inorg Chem."},{"issue":"25","key":"1125_CR48","first-page":"4159","volume":"2015","author":"D Tenne","year":"2015","unstructured":"Tenne D, Bogoslavsky B, Bino A. Ferric ammonium citrate\u2014what\u2019s in it? Inorg Chem. 2015;2015(25):4159\u201361.","journal-title":"Inorg Chem."},{"issue":"5560","key":"1125_CR49","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1126\/science.1067313","volume":"295","author":"AD Ferguson","year":"2002","unstructured":"Ferguson AD, Chakraborty R, Smith BS, et al. Structural basis of gating by the outer membrane transporter FecA. Science. 2002;295(5560):1715\u20139.","journal-title":"Science."},{"issue":"16","key":"1125_CR50","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1128\/JB.186.16.5303-5310.2004","volume":"186","author":"A Sauter","year":"2004","unstructured":"Sauter A, Braun V. Defined inactive FecA derivatives mutated in functional domains of the outer membrane transport and signaling protein of Escherichia coli K-12. J Bacteriol. 2004;186(16):5303\u201310.","journal-title":"J Bacteriol."},{"key":"1125_CR51","unstructured":"Kwok DWK, Stoynov NM, Inventors, Panion & BF Biotech, Inc., Assignee. Ferric organic compounds, uses thereof and methods of making same. US patent 7,767,851 B2, 3 Aug 2010."},{"key":"1125_CR52","unstructured":"Kwok DWK, Stoynov NM, Inventors; Panion & BF Biotech, Inc., Assignee. Ferric organic compounds, uses thereof and methods of making same. US patent 8,338,642 B2, 25 Dec 2012."},{"key":"1125_CR53","unstructured":"Kwok DWK, Stoynov NM, Inventors; Panion & BF Biotech, Inc., Assignee. Ferric organic compounds, uses thereof and methods of making same. US patent 8,609,896 B2, 17 Dec 2013."},{"key":"1125_CR54","unstructured":"Kwok DWK, Stoynov NM, Inventors; Panion & BF Biotech, Inc., Assignee. Ferric organic compounds, uses thereof and methods of making same. US patent 8,901,349 B2, 2 Dec 2014."},{"issue":"2","key":"1125_CR55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2478\/v10007-011-0020-8","volume":"61","author":"BP Badgujar","year":"2011","unstructured":"Badgujar BP, Mundada AS. The technologies used for developing orally disintegrating tablets: a review. Acta Pharm. 2011;61(2):117\u201339.","journal-title":"Acta Pharm."},{"issue":"6","key":"1125_CR56","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1681\/ASN.2016101053","volume":"28","author":"S Fishbane","year":"2017","unstructured":"Fishbane S, Block GA, Loram L, et al. Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia. J Am Soc Nephrol. 2017;28(6):1851\u20138.","journal-title":"J Am Soc Nephrol."},{"issue":"31","key":"1125_CR57","doi-asserted-by":"publisher","first-page":"12727","DOI":"10.1074\/jbc.R117.781823","volume":"292","author":"R Coffey","year":"2017","unstructured":"Coffey R, Ganz T. Iron homeostasis: an anthropocentric perspective. J Biol Chem. 2017;292(31):12727\u201334.","journal-title":"J Biol Chem."},{"issue":"4","key":"1125_CR58","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","volume":"93","author":"T Ganz","year":"2013","unstructured":"Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93(4):1721\u201341.","journal-title":"Physiol Rev."},{"issue":"4","key":"1125_CR59","doi-asserted-by":"publisher","first-page":"G397","DOI":"10.1152\/ajpgi.00348.2013","volume":"307","author":"S Gulec","year":"2014","unstructured":"Gulec S, Anderson GJ, Collins JF. Mechanistic and regulatory aspects of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol. 2014;307(4):G397\u2013409.","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"issue":"1","key":"1125_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","volume":"3","author":"P Geisser","year":"2011","unstructured":"Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011;3(1):12\u201333.","journal-title":"Pharmaceutics."},{"issue":"3","key":"1125_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10534-007-9116-5","volume":"21","author":"B Dresow","year":"2008","unstructured":"Dresow B, Petersen D, Fischer R, et al. Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals. 2008;21(3):273\u20136.","journal-title":"Biometals."},{"issue":"6","key":"1125_CR62","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/ki.1989.290","volume":"36","author":"DP Froment","year":"1989","unstructured":"Froment DP, Molitoris BA, Buddington B, et al. Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate. Kidney Int. 1989;36(6):978\u201384.","journal-title":"Kidney Int."},{"issue":"35","key":"1125_CR63","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.3748\/wjg.v13.i35.4716","volume":"13","author":"P Sharp","year":"2007","unstructured":"Sharp P, Srai SK. Molecular mechanisms involved in intestinal iron absorption. World J Gastroenterol. 2007;13(35):4716\u201324.","journal-title":"World J Gastroenterol."},{"issue":"1","key":"1125_CR64","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1096\/fj.15-276840","volume":"30","author":"JC Deschemin","year":"2016","unstructured":"Deschemin JC, Noordine ML, Remot A, et al. The microbiota shifts the iron sensing of intestinal cells. FASEB J. 2016;30(1):252\u201361.","journal-title":"FASEB J."},{"key":"1125_CR65","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.2147\/DDDT.S81863","volume":"9","author":"JE Toblli","year":"2015","unstructured":"Toblli JE, Cao G, Angerosa M. Ferrous sulfate, but not iron polymaltose complex, aggravates local and systemic inflammation and oxidative stress in dextran sodium sulfate-induced colitis in rats. Drug Des Devel Ther. 2015;9:2585\u201397.","journal-title":"Drug Des Devel Ther."},{"issue":"2","key":"1125_CR66","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1152\/physrev.00040.2012","volume":"94","author":"A Bhattacharyya","year":"2014","unstructured":"Bhattacharyya A, Chattopadhyay R, Mitra S, et al. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev. 2014;94(2):329\u201354.","journal-title":"Physiol Rev."},{"issue":"2","key":"1125_CR67","doi-asserted-by":"publisher","first-page":"e0117383","DOI":"10.1371\/journal.pone.0117383","volume":"10","author":"Z Tolkien","year":"2015","unstructured":"Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117383.","journal-title":"PLoS One."},{"issue":"2","key":"1125_CR68","doi-asserted-by":"publisher","first-page":"G354","DOI":"10.1152\/ajpgi.00422.2002","volume":"285","author":"FJ Troost","year":"2003","unstructured":"Troost FJ, Saris WH, Haenen GR, et al. New method to study oxidative damage and antioxidants in the human small bowel: effects of iron application. Am J Physiol Gastrointest Liver Physiol. 2003;285(2):G354\u20139.","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"1125_CR69","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/msb4100135","volume":"3","author":"DJ Dwyer","year":"2007","unstructured":"Dwyer DJ, Kohanski MA, Hayete B, et al. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol Syst Biol. 2007;3:91.","journal-title":"Mol Syst Biol."},{"issue":"3","key":"1125_CR70","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2559.2008.03081.x","volume":"53","author":"P Kaye","year":"2008","unstructured":"Kaye P, Abdulla K, Wood J, et al. Iron-induced mucosal pathology of the upper gastrointestinal tract: a common finding in patients on oral iron therapy. Histopathology. 2008;53(3):311\u20137.","journal-title":"Histopathology."},{"issue":"7","key":"1125_CR71","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1365-2559.2006.02448.x","volume":"48","author":"A Haig","year":"2006","unstructured":"Haig A, Driman DK. Iron-induced mucosal injury to the upper gastrointestinal tract. Histopathology. 2006;48(7):808\u201312.","journal-title":"Histopathology."},{"issue":"2","key":"1125_CR72","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1681\/ASN.2014020212","volume":"26","author":"JB Lewis","year":"2015","unstructured":"Lewis JB, Sika M, Koury MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015;26(2):493\u2013503.","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"1125_CR73","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5414\/CN109057","volume":"88","author":"DJ Hain","year":"2017","unstructured":"Hain DJ, Marinaro M, Koeper DW, et al. Ferric citrate controls serum phosphorus in dialysis patients: retrospective data. Clin Nephrol. 2017;88(1):12\u20138.","journal-title":"Clin Nephrol."},{"issue":"5","key":"1125_CR74","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1053\/j.ajkd.2012.11.041","volume":"61","author":"JP Dwyer","year":"2013","unstructured":"Dwyer JP, Sika M, Schulman G, et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis. 2013;61(5):759\u201366.","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"1125_CR75","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","volume":"65","author":"GA Block","year":"2015","unstructured":"Block GA, Fishbane S, Rodriguez M, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5. Am J Kidney Dis. 2015;65(5):728\u201336.","journal-title":"Am J Kidney Dis."},{"issue":"1\u20132","key":"1125_CR76","doi-asserted-by":"publisher","first-page":"c25","DOI":"10.1159\/000341922","volume":"121","author":"M Sinsakul","year":"2012","unstructured":"Sinsakul M, Sika M, Koury M, et al. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract. 2012;121(1\u20132):c25\u20139.","journal-title":"Nephron Clin Pract."},{"key":"1125_CR77","volume-title":"The effect of ferric citrate on IV iron, ESA utilization, and laboratory parameters in real-world dialysis patients","author":"CP Kovesdy","year":"2017","unstructured":"Kovesdy CP, Rowan CG, Foote B, et al. The effect of ferric citrate on IV iron, ESA utilization, and laboratory parameters in real-world dialysis patients. New Orleans: American Society of Nephrology; 2017."},{"key":"1125_CR78","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2369-15-55","volume":"15","author":"W Chen","year":"2014","unstructured":"Chen W, Abramowitz MK. Metabolic acidosis and the progression of chronic kidney disease. BMC Nephrol. 2014;15:55.","journal-title":"BMC Nephrol."},{"key":"1125_CR79","unstructured":"Hsu CH, Inventor. Methods for treating renal failure. US patent 5,753,706, 19 May 1998."},{"issue":"6","key":"1125_CR80","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","volume":"30","author":"J Floege","year":"2015","unstructured":"Floege J, Covic AC, Ketteler M, et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015;30(6):1037\u201346.","journal-title":"Nephrol Dial Transplant."},{"key":"1125_CR81","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1475-2891-13-71","volume":"13","author":"X Duque","year":"2014","unstructured":"Duque X, Martinez H, Vilchis-Gil J, et al. Effect of supplementation with ferrous sulfate or iron bis-glycinate chelate on ferritin concentration in Mexican schoolchildren: a randomized controlled trial. Nutr J. 2014;13:71.","journal-title":"Nutr J."},{"issue":"4","key":"1125_CR82","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1053\/j.jrn.2014.03.006","volume":"24","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Akiba T, Fukagawa M, et al. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. J Ren Nutr. 2014;24(4):261\u20137.","journal-title":"J Ren Nutr."},{"issue":"3","key":"1125_CR83","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1053\/j.ajkd.2015.03.013","volume":"66","author":"PN Van Buren","year":"2015","unstructured":"Van Buren PN, Lewis JB, Dwyer JP, et al. The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial. Am J Kidney Dis. 2015;66(3):479\u201388.","journal-title":"Am J Kidney Dis."},{"key":"1125_CR84","volume-title":"A prospective study examining the contribution to renal anemia treatment of ferric citrate hydrate, an iron-based oral phosphate binder, in hemodialysis patients with hyperphosphatemia: ASTRIO study (SA-PO818)","author":"K Yokoyama","year":"2017","unstructured":"Yokoyama K, Fukagawa M, Akiba T, et al. A prospective study examining the contribution to renal anemia treatment of ferric citrate hydrate, an iron-based oral phosphate binder, in hemodialysis patients with hyperphosphatemia: ASTRIO study (SA-PO818). New Orleans: American Society of Nephrology; 2017."},{"key":"1125_CR85","doi-asserted-by":"publisher","first-page":"j2513","DOI":"10.1136\/bmj.j2513","volume":"357","author":"AU Kelly","year":"2017","unstructured":"Kelly AU, McSorley ST, Patel P, et al. Interpreting iron studies. BMJ. 2017;357:j2513.","journal-title":"BMJ."},{"issue":"12","key":"1125_CR86","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1017\/S0007114511004971","volume":"107","author":"MC Lomer","year":"2012","unstructured":"Lomer MC, Cook WB, Jan-Mohamed HJ, et al. Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease. Br J Nutr. 2012;107(12):1806\u201311.","journal-title":"Br J Nutr."},{"issue":"3","key":"1125_CR87","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/MOH.0b013e3280d2b76b","volume":"14","author":"JC Wood","year":"2007","unstructured":"Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007;14(3):183\u201390.","journal-title":"Curr Opin Hematol."},{"issue":"6","key":"1125_CR88","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s12185-011-0878-8","volume":"93","author":"M Kobune","year":"2011","unstructured":"Kobune M, Miyanishi K, Takada K, et al. Establishment of a simple test for iron absorption from the gastrointestinal tract. Int J Hematol. 2011;93(6):715\u20139.","journal-title":"Int J Hematol."},{"key":"1125_CR89","volume-title":"Full prescribing information","author":"Venofer (Iron Sucrose Injection)","year":"2015","unstructured":"Venofer (Iron Sucrose Injection). Full prescribing information. St Gallen: Vifor (International) Inc.; 2015."},{"issue":"1","key":"1125_CR90","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2215\/CJN.04190510","volume":"6","author":"P Ferrari","year":"2011","unstructured":"Ferrari P, Kulkarni H, Dheda S, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(1):77\u201383.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"Pt 4","key":"1125_CR91","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/000456328101800405","volume":"18","author":"RW Blunden","year":"1981","unstructured":"Blunden RW, Lloyd JV, Rudzki Z, et al. Changes in serum ferritin levels after intravenous iron. Ann Clin Biochem. 1981;18(Pt 4):215\u20137.","journal-title":"Ann Clin Biochem."},{"issue":"6","key":"1125_CR92","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1111\/j.1523-1755.2005.00758.x","volume":"68","author":"DB Van Wyck","year":"2005","unstructured":"Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846\u201356.","journal-title":"Kidney Int."},{"issue":"5","key":"1125_CR93","first-page":"329","volume":"40","author":"A Pennoyer","year":"2015","unstructured":"Pennoyer A, Bridgeman MB. Ferric citrate (Auryxia) for the treatment of hyperphosphatemia. Pharm Ther. 2015;40(5):329\u201339.","journal-title":"Pharm Ther"},{"issue":"3","key":"1125_CR94","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2215\/CJN.05170513","volume":"9","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014;9(3):543\u201352.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"1125_CR95","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1159\/000344008","volume":"36","author":"K Yokoyama","year":"2012","unstructured":"Yokoyama K, Hirakata H, Akiba T, et al. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol. 2012;36(5):478\u201387.","journal-title":"Am J Nephrol."},{"issue":"10","key":"1125_CR96","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1681\/ASN.2014080842","volume":"26","author":"K Umanath","year":"2015","unstructured":"Umanath K, Jalal DI, Greco BA, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015;26(10):2578\u201387.","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"1125_CR97","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1159\/000489964","volume":"47","author":"N Maruyama","year":"2018","unstructured":"Maruyama N, Otsuki T, Yoshida Y, et al. Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin responsiveness in hemodialysis patients. Am J Nephrol. 2018;47(6):406\u201314.","journal-title":"Am J Nephrol."},{"issue":"6","key":"1125_CR98","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.2215\/CJN.02380607","volume":"2","author":"S Fishbane","year":"2007","unstructured":"Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol. 2007;2(6):1274\u201382.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"1125_CR99","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1681\/ASN.2018080858","volume":"30","author":"E Lin","year":"2019","unstructured":"Lin E, Bhattacharya J, Chertow GM. Prior hospitalization burden and the relatedness of 30-day readmissions in patients receiving hemodialysis. J Am Soc Nephrol. 2019;30(2):323\u201335.","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"1125_CR100","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1586\/14737167.2015.995169","volume":"15","author":"R Rodby","year":"2015","unstructured":"Rodby R, Umanath K, Niecestro R, et al. Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):545\u201350.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"3","key":"1125_CR101","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40268-015-0103-y","volume":"15","author":"RA Rodby","year":"2015","unstructured":"Rodby RA, Umanath K, Niecestro R, et al. Ferric citrate, an iron-based phosphate binder, reduces health care costs in patients on dialysis based on randomized clinical trial data. Drugs R D. 2015;15(3):271\u20139.","journal-title":"Drugs R D."},{"issue":"1","key":"1125_CR102","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40268-016-0163-7","volume":"17","author":"SM Brunelli","year":"2017","unstructured":"Brunelli SM, Sibbel SP, Van Wyck D, et al. Net budgetary impact of ferric citrate as a first-line phosphate binder for the treatment of hyperphosphatemia: a Markov microsimulation model. Drugs R D. 2017;17(1):159\u201366.","journal-title":"Drugs R D."},{"key":"1125_CR103","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ebiom.2018.11.020","volume":"39","author":"G Rostoker","year":"2019","unstructured":"Rostoker G, Loridon C, Griuncelli M, et al. Liver iron load influences hepatic fat fraction in end-stage renal disease patients on dialysis: a proof of concept study. EBioMedicine. 2019;39:461\u201371.","journal-title":"EBioMedicine."},{"key":"1125_CR104","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ebiom.2019.01.005","volume":"40","author":"R Chinnadurai","year":"2019","unstructured":"Chinnadurai R, Macdougall IC, Kalra PA. Treatment of anaemia in end-stage renal disease: a double-edged iron sword? EBioMedicine. 2019;40:31\u20132.","journal-title":"EBioMedicine."},{"key":"1125_CR105","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy318","author":"GA Block","year":"2018","unstructured":"Block GA, Pergola PE, Fishbane S, et al. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses. Nephrol Dial Transpl. 2018. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfy318\n                    \n                  .","journal-title":"Nephrol Dial Transpl."},{"key":"1125_CR106","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fendo.2018.00189","volume":"9","author":"B Richter","year":"2018","unstructured":"Richter B, Faul C. FGF23 actions on target tissues\u2014with and without klotho. Front Endocrinol (Lausanne). 2018;9:189.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"1125_CR107","volume-title":"Ferric citrate administration reduces FGF23 production and improves renal function in a mouse model of CKD (FR-ORO70)","author":"C Francis","year":"2017","unstructured":"Francis C, Courbon G, Neuburg S, et al. Ferric citrate administration reduces FGF23 production and improves renal function in a mouse model of CKD (FR-ORO70). New Orleans: American Society of Nephrology; 2017."},{"issue":"suppl 1","key":"1125_CR108","doi-asserted-by":"publisher","first-page":"i637","DOI":"10.1093\/ndt\/gfy146.LB05","volume":"33","author":"G Block","year":"2018","unstructured":"Block G, Block M, Smits G, et al. Randomized trial of the effects of ferric citrate in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2018;33(suppl 1):i637\u20138.","journal-title":"Nephrol Dial Transplant."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01125-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01125-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01125-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T23:30:31Z","timestamp":1590449431000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01125-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,27]]},"references-count":108,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01125-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,27]]},"assertion":[{"value":"27 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"TG is a scientific cofounder and shareholder of Intrinsic LifeSciences and Silarus Pharma. He is a consultant for Ablynx, Ambys,\u00a0Akebia Therapeutics, Gilead,\u00a0Global Blood Therapeutics, Keryx Biopharmaceuticals, La Jolla Pharmaceutical Company, Sierra Oncology\u00a0and Vifor. He has received Grant support from Akebia Therapeutics and Keryx Biopharmaceuticals. AB was a consultant to Keryx and received support for characterizing the structural composition of Auryxia. IBS is a consultant for Akebia Therapeutics, Keryx Biopharmaceuticals, Amgen, and Ultragenyx. He has received Grant support from Amgen and AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Support was provided by Keryx Biopharmaceuticals, Inc., which is now a wholly owned subsidiary of Akebia Therapeutics, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}